Real-world evaluation of bebtelovimab effectiveness during the period of COVID-19 Omicron variants, including BA.4/BA.5

OBJECTIVES: Bebtelovimab is an anti-SARS-CoV-2 monoclonal antibody active against Omicron lineage variants authorized to treat high-risk outpatients with COVID-19. We sought to determine the real-world effectiveness of bebtelovimab during the Omicron phases BA.2/BA2.12.1/BA4/BA5. METHODS: We conduct...

Descripción completa

Detalles Bibliográficos
Autores principales: Molina, Kyle C., Kennerley, Victoria, Beaty, Laurel E., Bennett, Tellen D., Carlson, Nichole E., Mayer, David A., Peers, Jennifer L., Russell, Seth, Wynia, Matthew K., Aggarwal, Neil R., Ginde, Adit A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10106116/
https://www.ncbi.nlm.nih.gov/pubmed/37072054
http://dx.doi.org/10.1016/j.ijid.2023.04.396

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10106116/
https://www.ncbi.nlm.nih.gov/pubmed/37072054
http://dx.doi.org/10.1016/j.ijid.2023.04.396

Ejemplares similares